Hayden Library - QP363.2.N47 2017

For children and young adults with certain relapsed B-cell acute lymphoblastic leukemia (B-ALL), the immunotherapy drug blinatumomab is superior to standard chemotherapy, an NCI-sponsored Children’s Oncology Group trial shows.

Online news editor David Grimm shares stories on yeasty hitchhikers, sunlight-induced rockfalls, and the tiniest gravity sensor.   Andrea Adamo joins host Sarah Crespi to discuss a revolutionary way of making drugs using a portable, on-demand, and reconfigurable drug factory.     [Image: Tom Evans]

This week we hear stories about putting rescue bots to the test after the Mexico earthquake, why a Scottish village was buried in sand during the Little Ice Age, and efforts by the U.S. military to predict posttraumatic stress disorder with Online News Editor David Grimm. Andrew Wagner interviews Alexandra Tinnermann of the University Medical Center of Hamburg, Germany, about the nocebo effect. Unlike the placebo effect, in which you get positive side effects with no treatment, in the nocebo effect you get negative side effects with no treatment. It turns out both nocebo and placebo effects get stronger with a drug perceived as more expensive. Read the research. Listen to previous podcasts. [Image: Chris Burns/Science; Music: Jeffrey Cook]

Armed with new data, archaeologists are revealing that mind-altering drugs were present at the dawn of the first complex societies some 5000 years ago in the ancient Middle East. Contributing writer Andrew Lawler joins Sarah Crespi to discuss the evidence for these drugs and how they might have impacted early societies and beliefs. Sarah also interviews Sarah Hobbie of the University of Minnesota about the fate of plants under climate change. Will all that extra carbon dioxide in the air be good for certain types of flora? A 20-year long study published this week in Science suggests theoretical predictions have been off the mark. This week’s episode was edited by Podigy. Listen to previous podcasts. [Image: Public domain Music: Jeffrey Cook]

About one-third of people with epilepsy are treatment resistant. Up until now, epilepsy treatments have focused on taming seizures rather than the source of the disease and for good reason—so many roads lead to epilepsy: traumatic brain injury, extreme fever and infection, and genetic disorders, to name a few. Staff Writer Jennifer Couzin-Frankel talks with host Sarah Crespi about researchers that are turning back the pages on epilepsy, trying to get to the beginning of the story where new treatments might work. And Sarah also talks with Torsten Neurbert at the Technical University of Denmark’s National Space Institute in Kongens Lyngby about capturing high-altitude “transient luminous events” from the International Space Station (ISS). These lightning-induced bursts of light, color, and occasionally gamma rays were first reported in the 1990s but had only been recorded from the ground or aircraft. With new measurements from the ISS come new insights into the anatomy of lightning. This week’s episode was edited by Podigy. Ads on this week’s show: Bayer; Lightstream; KiwiCo Download a transcript (PDF) Listen to previous podcasts. About the Science Podcast [Image: Gemini Observatory; Music: Jeffrey Cook]

These are the most important oncology stories you need to know about today.
Medscape Medical News

New York : Springer, [2007]

Cambridge, Mass. : National Bureau of Economic Research, 2020

Dewey Library - HV5801.Z54 2019

He gave sweets laced with drugs before pushing all three into the canal: Police

Online Resource

Interview with Aaron Kesselheim, author of Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs, and Francis J. Crosson, M.D., author of Managing the Cost of Medicare Part B Drugs: Implications for the Program and Beneficiaries

Interview with Christopher W. Goodman, MD, author of A Clinical Overview of Off-label Use of Gabapentinoid Drugs

Guidelines include how to deal with pesky interfering signals when making voltammetric sensors

A large number of diseases have been linked to the NLRP3 inflammasome. The race is on to develop drugs that disrupt it

Venture will combine six active pharmaceutical ingredient production sites in Europe

Venture will combine 6 active pharmaceutical ingredient production sites in Europe

Her company, Esya Labs, is developing DNA nanodevices that track drug responses, screen for new therapies, and more

Hear what C&EN's pharmaceutical editors have learned about how the coronavirus is affecting drug production in China and across the globe

Several approved and well-studied small molecules could be repurposed as treatments for COVID-19

New study explores whether dampening IL-6 could address serious coronavirus infections

They persist in the pharma business, even as chemical companies in the West have mostly exited

Medicinal chemists focus on the main protease of SARS-CoV-2 to develop antiviral treatments for the virus causing COVID-19

Medicinal chemists focus on the main protease of SARS-CoV-2 to develop antiviral treatments for COVID-19

The chemist wants the Gates Foundation–backed institute to share its expertise during the coronavirus pandemic and advocate for public health

Country will now allow exports if domestic needs are met to treat COVID-19

Advances in chemistry have led to a comeback for ADCs, with more on the way